Panagora Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Panagora Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.4M	Sell	182,235 -443,343	-71%	-$6.45M	0.01%	523
2026 Q1	$7.46M	Sell	625,578 -67,423	-10%	-$755K	0.03%	346
2025 Q4	$8.68M	Buy	693,001 +122,533	+21%	+$1.42M	0.03%	311
2025 Q3	$5.22M	Buy	570,468 +766	+0.1%	+$5.74K	0.02%	358
2025 Q2	$3.12M	Buy	569,702 +229,798	+68%	+$1.43M	0.01%	395
2025 Q1	$2.14M	Buy	339,904 +219,600	+183%	+$1.05M	0.01%	494
2024 Q4	$496K	Buy	120,304 +95,403	+383%	+$305K	﹤0.01%	840
2024 Q3	$83.2K	Buy	+24,901	New	+$74K	﹤0.01%	1183
2020 Q2	–	Sell	-406	Closed	-$1K	–	2653
2020 Q1	$1K	Hold	406	–	–	﹤0.01%	2455
2019 Q4	$2K	Hold	406	–	–	﹤0.01%	2364
2019 Q3	$2K	Buy	+406	New	+$2.21K	﹤0.01%	2376

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Panagora Asset Management's TRVI Position: Q2 2026 in Review

Panagora Asset Management reduced its Trevi Therapeutics (TRVI) stake by 71% in Q2 2026, selling an estimated $6.45M and leaving 182,235 shares worth $3.4M. The position accounts for 0.01% of the portfolio, ranked #523.

Panagora Asset Management first reported a position in TRVI in Q3 2019 and has held it in 11 quarters since. The position peaked at $8.68M in Q4 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Panagora Asset Management held 182,235 shares of Trevi Therapeutics worth $3.4M as of Q2 2026.
Panagora Asset Management sold 443,343 Trevi Therapeutics shares in Q2 2026, an estimated $6.45M.
Trevi Therapeutics made up 0.01% of Panagora Asset Management's portfolio in Q2 2026, its #523 holding.
Panagora Asset Management first reported a position in Trevi Therapeutics in Q3 2019 and has held it in 11 quarters since.
Panagora Asset Management's Trevi Therapeutics position peaked at $8.68M in Q4 2025.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.